Aligos Therapeutics, Inc. (ALGS)
Company Info
| ISIN | US01626L1052 |
|---|---|
| CUSIP | 01626L105 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $1.31B |
|---|---|
| EPS | $9.35 |
| PE Ratio | 7.63 |
| PEG Ratio | -14.47 |
| Revenue (TTM) | $2.51B |
| Gross Profit (TTM) | $494.21M |
| EBITDA (TTM) | $478.09M |
| Year Range | $54.32 - $128.87 |
| Target Price | $89.20 |
| Short % | 6.72% |
| Short Ratio | 2.90 |
Share Price Chart
Loading data...
Performance
The chart shows the growth of an initial investment of $10,000 in Aligos Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Compare to other instruments
Return
Aligos Therapeutics, Inc. had a return of -26.42% year-to-date (YTD) and -27.35% in the last 12 months.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -26.42% | 19.67% |
| 1 month | -6.52% | 8.42% |
| 6 months | -41.08% | 7.29% |
| 1 year | -27.35% | 12.71% |
| 5 years (annualized) | N/A | 10.75% |
| 10 years (annualized) | N/A | 9.87% |
Monthly Returns Heatmap
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | -2.59% | -14.07% | -8.34% | -3.26% | -13.24% | -19.68% | 16.67% |
Risk-Adjusted Performance
This table presents a comparison of risk-adjusted performance metrics for Aligos Therapeutics, Inc. (ALGS) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| Sharpe ratio | Sortino ratio | Omega ratio | Calmar ratio | Ulcer Index | |
|---|---|---|---|---|---|
ALGS Aligos Therapeutics, Inc. | -0.33 | ||||
^GSPC S&P 500 | 0.91 |
Dividend History
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Aligos Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Aligos Therapeutics, Inc. was 98.31%, occurring on Nov 14, 2023. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.31% | Jan 21, 2021 | 710 | Nov 14, 2023 | — | — | — |
| -22.62% | Nov 17, 2020 | 10 | Dec 1, 2020 | 8 | Dec 11, 2020 | 18 |
| -20.62% | Dec 24, 2020 | 4 | Dec 30, 2020 | 9 | Jan 13, 2021 | 13 |
| -11.11% | Oct 19, 2020 | 2 | Oct 20, 2020 | 1 | Oct 21, 2020 | 3 |
| -10.79% | Nov 10, 2020 | 1 | Nov 10, 2020 | 3 | Nov 13, 2020 | 4 |
Volatility Chart
The current Aligos Therapeutics, Inc. volatility is 27.50%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.